The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is associated with all features of the metabolic syndrome. Although deposition of excess triglycerides within liver cells, a hallmark of NAFLD, is associated with a loss of insulin sensitivity, it is not clear which cellular abnormality arises first. We have explored this in mice overexpressing carbohydrate responsive element-binding protein (ChREBP). On a standard diet, mice overexpressing ChREBP remained insulin sensitive, despite increased expression of genes involved in lipogenesis/fatty acid esterification and resultant hepatic steatosis (simple fatty liver). Lipidomic analysis revealed that the steatosis was associated with increased accumulation of monounsaturated fatty acids (MUFAs). In primary cultures of mouse hepatocytes, ChREBP overexpression induced expression of stearoyl-CoA desaturase 1 (Scd1), the enzyme responsible for the conversion of saturated fatty acids (SFAs) into MUFAs. SFA impairment of insulin-responsive Akt phosphorylation was therefore rescued by the elevation of Scd1 levels upon ChREBP overexpression, whereas pharmacological or shRNA-mediated reduction of Scd1 activity decreased the beneficial effect of ChREBP on Akt phosphorylation. Importantly, ChREBP-overexpressing mice fed a high-fat diet showed normal insulin levels and improved insulin signaling and glucose tolerance compared with controls, despite having greater hepatic steatosis. Finally, ChREBP expression in liver biopsies from patients with nonalcoholic steatohepatitis was increased when steatosis was greater than 50% and decreased in the presence of severe insulin resistance. Together, these results demonstrate that increased ChREBP can dissociate hepatic steatosis from insulin resistance, with beneficial effects on both glucose and lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In this regard, ChREBP expression in liver biopsies from patients with MASH was observed to be two-fold higher when the histologic steatosis score was greater than 50% compared to those with less than 50%.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
The cited source says what the claim attributes to it.
In the citing paper
“However, it decreased in the presence of severe IR [34,94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
In the citing paper
“Transient overexpression of ChREBP in the liver results in hepatic steatosis without IR through induction of the lipogenic enzyme SCD1, suggesting that increased ChREBP can dissociate hepatic steatosis from IR [94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
In the citing paper
“Transient overexpression of ChREBP in the liver results in hepatic steatosis without IR through induction of the lipogenic enzyme SCD1, suggesting that increased ChREBP can dissociate hepatic steatosis from IR [94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
In the citing paper
“Taken together, these findings demonstrate that ChREBP-driven hepatic steatosis can be dissociated from IR [94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · cited 1×
“genes was achieved by the ΔΔCt method (88).”
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“(91): 0, absent; 1, <5%; 2, 5%–33%; 3, 33%–66%; 4, >66%.”
Signal integration in the endoplasmic reticulum unfolded protein response
Ron, D., & Walter, P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2199 · Cited by 6,296 · cited 1×
“UPR induces transcription of a set of genes whose protein products increase the capacity for protein folding and ER-associated degradation and induces apoptosis when the ER function is severely impaired (41, 42).”
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907 · cited 11×
“To our knowledge, our work is the first to report that hepatic ChREBP expression varies positively according to the degree of steatosis and inversely to insulin resistance in a cohort of patients with NASH.”
InfluentialDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 5×
“Using a multiple-stable-isotope approach, Don-nelly et al. (16) estimated that, of the TG content accounted for in the livers of patients with NAFLD, 60% arose from NEFA, a little over 10% came from the diet, and close to 30% came from de novo lipogenesis, underlying the importance of de novo TG synthesis in the etiol…”
InfluentialNutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Triglyceride accumulation protects against fatty acid-induced lipotoxicity
Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Ory, D. S., & Schaffer, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630588100 · Cited by 2,075 · cited 17×
“Recent studies have revealed that chronic SFA exposure activates unfolded protein response (UPR) in cultured cells (39, 40).”
InfluentialPGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure
Cantó, C., & Auwerx, J. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328328d0a4 · Cited by 1,624 · cited 1×
“In the liver, SIRT1 controls gluconeogenic activity by modulating the acetylation levels of a network of transcription factors and/or coactivators, including PPARGC1A (74–76).”
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495 · cited 1×
“We also measured the expression of fibroblast growth factor 21 (FGF21), a key metabolic regulator whose expression is regulated via PPAR pathways during states requiring increased fatty acid oxidation (33).”
Research works printed but not linked: 2
- Denechaud, 2008, J Clin Invest., 118, 956
- Dentin R, et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes . 2006;55(8):2159-2170. · DOI · Paper page
Cited by
Items 301–400 of 405
Role of ChREBP and SREBP-1c in gestational diabetes: two key players in glucose and lipid metabolism
Eroğlu, N., Yerlikaya, F. H., Onmaz, D. E., & Çolakoğlu, M. C. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01050-x · Cited by 7
“However, it has been reported that increased expression of hepatic ChREBPmay increase the synthesis of beneficial lipid species and reduce harmful species by increasing SCD1 expression [18].”
A Review of Defatting Strategies for Non-Alcoholic Fatty Liver Disease
Young, E. N., Doğan, M., Watkins, C. E., Bajwa, A., Eason, J. D., Kuscu, C., & Kuscu, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911805 · Cited by 7
“As detailed, both transcription factors of DNL play important roles in the pathogenesis of NAFLD, however, it was concluded that SREBP1c is the predominant regulator [60].”
BackgroundInfluentialLe facteur de transcription ChREBP: Un modulateur clé de la sensibilité à l’insuline ?
Benhamed, F., Poupeau, A., & Postic, C. (2013) · médecine/sciences · doi:10.1051/medsci/2013298016 · Cited by 10
Self-citationGehring, J., Azzout‐Marniche, D., Chaumontet, C., Piedcoq, J., Gaudichon, C., & Even, P. C. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00246.2021 · Cited by 8
Starr, C. R., Zhylkibayev, A. A., Gorbatyuk, O. S., Nuotio-Antar, A. M., Mobley, J. A., Grant, M. B., & Gorbatyuk, M. S. (2025) · Cells · doi:10.3390/cells14020107 · Cited by 5
“For instance, in mice challenged with a high-fat diet, liver-specific ChREBP overexpression leads to elevated serum triglycerides and increased inflammation [10,11].”
Horn, M., Gumede, N. M., & Gamede, M. W. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118633 · Cited by 6
Gál, A. R., Szokodi, I., Vizvári, Z., Győrfi, N., Vereczkei, A. G., Petykó, Z., Karádi, Z., & Tóth, A. (2026) · Antioxidants · doi:10.3390/antiox15060710 · Cited by 7
“Excessive sugar ingestion, particularly fructose, drives hepatic lipogenesis through activation of ChREBP and can induce steatosis even independent of canonical insulin-mediated pathways [99,100].”
Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 7
“In animal models of MASLD, the deletion of hepatic ChREBP and SREBP1 prevents hepatic fat accumulation, reduces plasma levels of TG and ameliorates IR; the expression of ChREBP, SREBP1 and their targets also correlate with the degree of steatosis in MASLD patients [62, 72, 73].”
Elseweidy, M. M., Elnagar, G. M., El-Sawy, M. M., Ali, A. A., & Zein, N. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13363 · Cited by 5
“Histamine, a product originated from mast cells, can play several physiological functions, mostly mediated through histamine receptors mainly H1, H2, H3 and H4 receptors (H1R, H2R, H3R and H4R).([14]) Previous study had referred to its potential proatherogenic role in the pathophysiology of atherosclerosis.”
BackgroundThalla, S., Kamaraj, R., & Kavitha, A. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220104095534 · Cited by 5
Qin, X., Jiang, L., Zhao, P., Lin, Y., Zhang, Y., & Xia, Q. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063427 · Cited by 5
“Much evidence has also proven that the physiological function of Mondo-Mlx contributes to the regulation of lipid, carbohydrate and amino acid metabolic genes in mice or flies [20,29–31 ,33 , 37 , 41, 81 ].”
BackgroundAfruza, R., Akheruzzaman, M., Dhurandhar, N. V., & Hegde, V. K. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05261 · Cited by 4
“SREBP1c (member of SREBPs) [9], ChREBPs [13] and PPAR- α, β, γ [14] are all well-known transcription factors that regulate lipid metabolism.”
BackgroundRaza, I., Sohail, A., Muneer, H., Fayyaz, H., Uddin, Z., Almars, A. I., Aggad, W. S., Almohaimeed, H. M., & Ullah, I. (2024) · International Journal of Endocrinology · doi:10.1155/ije/3914332 · Cited by 5
ChREBP mediates metabolic remodeling in FBP1-deficient liver
Wang, C.-M., Bai, Q.-F., Liu, Y., Lin, J., Wei, C., Ma, X., Zhao, J.-M., Zhu, M., Chen, Y.-X., Shi, Y., et al. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00875.2024 · Cited by 5
Chaudhari, A., Krumlinde, D., Lundqvist, A., Akyürek, L. M., Bandaru, S., Skålén, K., Ståhlman, M., Borén, J., Wettergren, Y., Ejeskär, K., et al. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00471-15 · Cited by 5
The Role of Carbohydrate Response Element–Binding Protein in the Development of Liver Diseases
Iizuka, K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814466-4.00022-7 · Cited by 7
A high throughput screen for pharmacological inhibitors of the carbohydrate response element
You, S., & Bollong, M. J. (2023) · Scientific Data · doi:10.1038/s41597-023-02596-z · Cited by 3
“ChREBP overexpression in the liver of mice has been shown to increase hepatic steatosis 18 and genetic ChREBP ablation in the liver reverses hepatic steatosis 19 .”
BackgroundKrishnamurthy, K. A., Rutten, M. G. S., Hoogerland, J. A., van Dijk, T. H., Bos, T., Koehorst, M., de Vries, M. P., Kloosterhuis, N., Havinga, H., Schomakers, B. V., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101838 · Cited by 4
“In line with these data, hepatic ChREBP overexpression reduces he-patic Gck mRNA levels (gse61576) [35], while ChREBP knockout mice show increased Gck mRNA levels [11].”
BackgroundZoubiri, H., Saiah, W., Otmane, A., Saidi, H., Makrelouf, M., Abderrahman, S. A., Haddam, A. E. M., & Koceir, E.-A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031218 · Cited by 3
“This study was corroborated by another study which showed that the transcription of lipogenesis genes, including SREBP-1c, was activated by the glucose-signaling pathway, and that this was primarily related to the transcription factor ChREBP (carbohydrate responsive element-binding protein) [73].”
Zhong, Q., Zhang, Y., Sun, D., Peng, J., Zhang, P., Wang, R., Cao, L., Chen, H., Wu, C., & He, Z. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1788998 · Cited by 3
“Studies have shown that proximal tubular-speci fi c knockout of FASN or acetyl-CoA synthetase 2 in mice signi fi cantly reduces lipid deposition (55, 56).”
Li, J., Zhang, S., Sun, Y., Li, J. H., Feng, Z., Li, H., Zhang, M., Yan, T., Han, J., & Duan, Y. (2024) · EMBO Reports · doi:10.1038/s44319-024-00121-w · Cited by 4
“Meanwhile, overexpression of a constitutively active form of ChREBP in the male mouse liver increased hepatic steatosis but enhanced insulin sensitivity under high-fat diet (Benhamed et al, 2012).”
Thapa, K., Ghimire, B. R., Pokharel, K., Cai, M., Savontaus, E., & Rinne, P. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01600-9 · Cited by 3
Karim, M., Prey, J., Willer, F., Leiner, H., Yasser, M., Dombrowski, F., & Ribback, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052246 · Cited by 4
“In agreement with previous studies [26], the mRNA expression level of insulin signaling candidate IRS1 was increased in HFD groups in 12-week and 24-week periods (Supplementary Figure S5).”
Transcriptional Regulation of De Novo Lipogenesis in Liver
Zhang, D., & Yin, L. (2015) · Springer eBooks · doi:10.1007/978-3-319-25065-6_1 · Cited by 6
Lipids, Low-Grade Chronic Inflammation and NAFLD
Tarantino, G., & Finelli, C. (2016) · Elsevier eBooks · doi:10.1016/b978-1-63067-036-8.00028-7 · Cited by 4
Musengi, Y., Suciu, I., Tralau, T., & Bloch, D. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04071-7 · Cited by 4
“The toxicodynamic interactions of the active substances extend to the de novo fatty acid synthesis pathway, as evidenced by the combined upregulation of MLXIPL and FASN (Fig.”
Influentialde Assis, L. V. M., Jegodzinski, L., Inderhees, J., Wowro, S. J., Affonso, J. M., Heyde, I., Fischer, E. L., Schönfels, W. V., Schenk, A., Roßner, F., et al. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2026.101806 · Cited by 2
“Further analysis of Bmal1 -asso- ciated genes revealed several indirect regulators of energy metabolism (eg, Igf1 , Lbh , Rorc , and Foxa1 ) in addition to identifying Abca1 and Abca8b , key cholesterol efflux proteins (Figure 5 F and G ).”
Role of ChREBP–PPARα–FGF21 Axis in Metabolic Dysfunction of MASLD
Girón, K. M. P., Nazará, Z., Maldonado‐González, M., Martínez‐López, E., Sánchez-Muñoz, M. P., Bautista-López, C. A., Aldana-Aguiñaga, M. S., Domínguez-Rosales, J. A., Vargas‐Guerrero, B., & Ruiz‐Madrigal, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311425 · Cited by 3
“In this way, we support the observations of Benhamed F et al., who, without differentiating the ChREBP isoforms, concluded that ChREBP could dissociate the presence of steatosis and insulin resistance [98].”
Flavonoids in MASLD: preclinical mechanisms, pharmacological targets, and translational challenges
Dao, Z., Li, J., Liu, Y., Niu, D., Xiao, Z., & Dong, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1878277 · Cited by 2
“In addition, insulin resistance promotes hepatic lipogenesis by regulating transcription factors such as sterol regulatory element binding protein 1c (SREBP-1c) and carbohydrate response element binding protein (ChREBP) (Benhamed et al., 2012).”
Czynnik transkrypcyjny ChREBP â koordynator metabolizmu węglowodanów i lipidów
Krawczak, J., Owczarek, A., & Winiarska, K. (2020) · Postępy Biochemii · doi:10.18388/pb.2019_282 · Cited by 3
Glucokinase as a therapeutic target based on findings from the analysis of mouse models
Nakamura, A. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej21-0742 · Cited by 4
“However, tem‐ porally increased Chrebp-b expression would upregulate the expression of downstream lipogenesis-related genes, resulting in hepatic fat accumulation [40, 47, 49-52] (Fig.”
BackgroundHepatic ChREBP reciprocally modulates systemic insulin sensitivity in NAFLD
Sen, A., Thakur, S., Rawat, P., Jaswal, K., Dehury, B., & Mondal, P. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108556 · Cited by 4
“While primary hepatocyte-speci fi c ChREBP overexpression improved insulin sensitivity, a high-fat diet – fed mice model, which also shows increased ChREBP levels, showed insulin resistance (20, 21).”
Transcriptional regulation of lipogenesis and its contribution to hepatosteatosis
Wang, Y., & Sul, H. S. (2013) · Clinical Lipidology · doi:10.2217/clp.13.11 · Cited by 2
Medak, K. D., McKie, G. L., Peppler, W. T., Shamshoum, H., Dibe, H. A., Mutch, D. M., Josse, A. R., & Wright, D. C. (2023) · Nutrition Research · doi:10.1016/j.nutres.2023.09.003 · Cited by 2
Contribution of de novo lipogenesis to the progression of nonalcoholic fatty liver disease
Abdul, M. M. S. (2020) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/81575 · Cited by 2
Levi, M., Takahashi, S., Wang, X. X., & Levi, M. E. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch49 · Cited by 2
Adipocyte-specific deletion of gp130 prevents ketogenic diet–induced hepatic steatosis
Senkalfa, B., Gloor, M., Podlaszewski, R., Dewal, R. S., Horváth, C., Efthymiou, V., Ghosh, A., Wueest, S., Konrad, D., Wolfrum, C., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000782 · Cited by 1
“[12] 15] Furthermore, in obesity, adipose-derived cytokines like IL-6, TNF α , and IL-1 β activate and recruit macrophages to the liver, promoting liver inflammation, hepatocyte damage, and fibrosis.”
Morgado, J., Machado, I. F., Rolo, A. P., & Palmeira, C. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062599 · Cited by 2
“However, C57BL/6J mice overexpressing ChREBP on a high-fat diet also displayed increased insulin sensitivity and glucose tolerance despite also developing hepatic steatosis, which could mean that insulin resistance is not directly caused by ChREBP-induced fatty liver [49].”
Rezaei, S. A. S., Amirfiroozy, A., Kohkalani, M., & Mehri, M. (2026) · Current Diabetes Reviews · doi:10.2174/0115733998443779260129064444 · Cited by 4
ChREBP-mediated regulation of lipid metabolism in liver and brown adipose tissue of long-lived mice
Hager, M., Adam, C., Mercier, L., Voorhees, A., Lee, M., Ball, L., Yang, J., Bartke, A., Miller, R. A., & Li, X. (2026) · GeroScience · doi:10.1007/s11357-026-02263-2 · Cited by 1
Targeting mTOR with vistusertib attenuates metabolic steatohepatitis and prevents HCC development
Sharma, N., Panneerselvam, S., Chandra, Y., & Andugulapati, S. B. (2026) · Inflammation Research · doi:10.1007/s00011-026-02265-y · Cited by 1
“Resto-ration of ChREBP1 activity has been shown to rebalance hepatocellular lipid homeostasis [ 31 ] and mitigate the lipogenic and oncogenic pressures [ 32 ] that may inhibit MASH progression toward HCC.”
Non-pharmacological treatment of MASLD
Dufour, J., & Berzigotti, A. (2026) · Diabetologia · doi:10.1007/s00125-026-06811-5 · Cited by 1
“This is partly mediated by a high-fat diet and hyperglycaemia-associated induction of transcription factors, such as sterol regulatory element ‐ binding protein 1 (SREBP ‐ 1) and carbohydrate response element ‐ binding protein (ChREBP) [13, 14].”
Monteiro, J., McLennan, M., Hillyer, L. M., Askarian, F., Moghadasian, M. H., Nakamura, M., & David, W. L. (2012) · The FASEB Journal · doi:10.1096/fasebj.26.1_supplement.266.1 · Cited by 2
Hepatic lipid metabolism and non-alcoholic fatty liver disease
Qu, Y., & Han, Z. (2017) · Scientia Sinica Vitae · doi:10.1360/n052017-00103 · Cited by 1
Rajas, F., & Mithieux, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-849886-6.00021-5 · Cited by 2
Fanlian Huazhuo Formula: A promising herbal preparation for metabolic liver disease
Singla, B. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i46.4964 · Cited by 1
“Several proteins, including adenosine-5’-monophosphate-activated protein kinase, acetyl-CoA carboxylase (ACC), steroyl-CoA response element binding protein-1c, farnesoid X receptor, and carbohydrate response element-binding protein play important roles in de novo lipogenesis [22,23].”
Hexokinase regulates Mondo-mediated longevity via the PPP and organellar dynamics
Laboy, R., Ndoci, M., Syed, S. T., Vonolfen, M., Ballhysa, E., Droth, T., Schilling, K., Löhrke, A., Atanassov, I., & Antebi, A. (2023) · eLife · doi:10.7554/elife.89225.4 · Cited by 1
A new pathway to eSCAPe lipotoxicity
Benhamed, F., & Postic, C. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2017.10.005 · Cited by 1
Self-citationPhysiopathologie de la stéatose hépatique non-alcoolique (NAFLD)
Parlati, L., Régnier, M., Postic, C., & Guillou, H. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.03.005 · Cited by 3
Self-citationToward a Mechanistic Understanding of Hepatic Insulin Action and Resistance
Cook, J. R. (2014) · doi:10.7916/d8j38r4z · Cited by 1
Nutraceutical‐Based Pharmacological Intervention in the Management of Liver Diseases
Shah, A., & Mudassar, S. (2018) · Wiley eBooks · doi:10.1002/9781119436713.ch14 · Cited by 1
Ceddia, R. P., Zurawski, Z., Gray, A. T., Adegboye, F. O., McDonald-Boyer, A., Shi, F., Liu, D., Maldonado, J., Feng, J., Li, Y., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.29.069138 · Cited by 1
“Catheters were inserted 4-5 days prior to a study by the Metabolic Pathophysiology Core (41-43).”
MethodLevi, M. (2009) · Wiley eBooks · doi:10.1002/9780470747919.ch40
Ortiz-Vilchis, C. M. (2015) · Medicina e Investigación · doi:10.1016/j.mei.2015.02.009
Hepatic Mitochondrial Fatty Acid Oxidation and Type 2 Diabetes
Mansouri, A., Langhans, W., Girard, J. R., & Prip‐Buus, C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801585-8.00028-2
Self-citationThe role of ER stress in lipogenesis and insulin resistance in response to over nutrition
Sun, R. (2016) · RMIT Research Repository (RMIT University Library) · doi:10.25439/rmt.27581124
Role of Lipogenesis and Lipid Desaturases in Non-alcoholic Fatty Liver Disease
Lounis, M. A., Rial, S. A., Ntambi, J. M., & Mounier, C. (2015) · Springer eBooks · doi:10.1007/978-3-319-25065-6_7 · Cited by 1
Berlanga, A. (2015) · TDX (Tesis Doctorals en Xarxa)
Le microbiote et les stéatopathies métaboliques
Buffet, C. (2014) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)31172-0
Nutrients and Genes in the Liver
Cariello, M., Piccinin, E., García‐Irigoyen, O., & Moschetta, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-804572-5.00052-5
Regulation of Hepatic Fuel Utilization and Storage Through BAD-Dependent Glucose Signaling
Lane, E. A. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Farr, S. (2017) · TSpace (University of Toronto)
Rôle des hépatokines dans le dialogue inter-organes en physiologie et physiopathologie
Pacheco, A., & Postic, C. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.04.008 · Cited by 3
Self-citationThe roles of H2S on hepatic acetyl-CoA and lipid metabolism
Ali, A. (2020) · Lu Zone Ul (Laurentian University)
Integrin Signaling is a Novel Regulator of Hepatic Insulin Action
Williams, A. S. (2015)
Roumans, K. H. M. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210915kr
ZHX2 REGULATION OF LIPID METABOLISM AND THE BALANCE BETWEEN CARDIOVASCULAR AND HEPATIC HEALTH
Creasy, K. T. (2015) · UKnowledge (University of Kentucky)
Magnetic resonance spectroscopy to unravel metabolic alterations in hepatic steatosis in humans
Veeraiah, P. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210701pv
Molecular Basis of Liver Disease
Monga, S. P., & Behari, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802761-5.00020-1
Masi, L. N. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2014.tde-19112014-094237 · Cited by 1
Gu, L., Zhu, Y., Watari, K., Lee, M., Liu, J., Perez, S., Thai, M., Mayfield, J. E., Zhang, B., Rocha, K. C. E., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.05.531181
karawia, Z., & Mansour, M. A. (2023) · Zagazig Veterinary Journal/Zagazig Veterinary Journal (Online) · doi:10.21608/zvjz.2023.192324.1207 · Cited by 2
“Consequently, to advance hepatic steatosis in mice, both ACC1 and ACC2 needed to be inhibited [55].”
BackgroundHexokinase regulates Mondo-mediated longevity via the PPP and organellar dynamicsPreprint
Laboy, R., Ndoci, M., Vonolfen, M., Ballhysa, E., Atanassov, I., & Antebi, A. (2023) · eLife · doi:10.7554/elife.89225.1 · Cited by 1
Uncoupling of fat deposition and inflammation during nonalcoholic fatty liver disease
Li, H., Guo, X., Aquino, E., & Wu, C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95582-9.00012-7
Hepatic Safety in Rats Fed on Fructose, Glucose, or Sucrose When Combine with A Moderate Fat Diet
Nasr, N., Elkattawy, A. M., Kahilo, K. A., Sadek, K. M., Elhady, S. A., El-Sawy, H. B., & Dorghamm, D. A. (2023) · Egyptian Journal of Veterinary Science · doi:10.21608/ejvs.2023.230165.1563
“Human investigations have also revealed similar results, with raised SREBP1 levels in individuals with fatty liver disease [32], while an increase in total expression ChREBP has been reported in insulin-resistant steatosis states [33].”
ResultDong, B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91338-6.00027-6
Hexokinase regulates Mondo-mediated longevity via the PPP and organellar dynamicsPreprint
Laboy, R., Ndoci, M., Vonolfen, M., Ballhysa, E., Syed, S. T., Droth, T., Schilling, K., Löhrke, A., Atanassov, I., & Antebi, A. (2024) · eLife · doi:10.7554/elife.89225.2
Glucose-Sensing ChREBP Protein in the Pathogenesis of Diabetic RetinopathyPreprint
Starr, C. R., Zhylkibayev, A. A., Gorbatyuk, O. S., Nuotio-Antar, A. M., Mobley, J. A., Grant, M. B., & Gorbatyuk, M. S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.04.626828
“For instance, in mice challenged with a high-fat diet (HFD), liver-specific ChREBP overexpression leads to ele-56 vated serum triglycerides (TG) and increased inflammation [10,11].”
Vily‐Petit, J., Gautier‐Stein, A., & Mithieux, G. (2025) · médecine/sciences · doi:10.1051/medsci/2025023
Hexokinase regulates Mondo-mediated longevity via the PPP and organellar dynamicsPreprint
Laboy, R., Ndoci, M., Tabrez, S. S., Vonolfen, M., Ballhysa, E., Droth, T., Schilling, K., Löhrke, A., Atanassov, I., & Antebi, A. (2025) · eLife · doi:10.7554/elife.89225.3 · Cited by 1
Strużek, K., Kwiatkowska, A., Mączka, E., Tracz, W., Świercz, P., Teper, K., Khiralla-Gawlik, S., Strzelecka, A. A., & Basak, A. E. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3662
Shen, L., Lin, Y., Chen, W., Zhou, D., & Peng, H. (2025) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.70107
“Moreover, high TG levels exacerbate insulin resistance in peripheral tissues, establishing a vicious cycle that accelerates the progression of NAFLD [30–32].”
Fulham, M. A., Griffin, J. D., Perez, S., Sun, Z., Daurio, N. A., Xing, G., Clasquin, M. F., Miller, M. R., Hyde, C. L., Kelly, S. P., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102310 · Cited by 1
“Activation of ChREBP is important for lipogenesis as the absence of ChREBP α and ChREBP β blunts hepatic lipid synthesis and overexpression of ChREBP α in mice causes hepatic steatosis [28,31,60].”
Berlanga, A., Guiu‐Jurado, E., Porras, J. A., Aragonès, G., & Auguet, T. (2015) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.03.003 · Cited by 4
Mondo family proteins in diabetes
Barodia, S. K., Grant, M. B., & Gorbatyuk, M. S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1745162
Étude du rôle de la production hépatique de glucose dans le développement du diabète et de l’obésité
Abdul-Wahed, A. (2012) · theses.fr (ABES) · doi:10.70675/61924053za287z4f04zb650zc51c1916ee64
Homéostasie des céramides et hépatopathies métaboliques
Régnier, M. (2018) · theses.fr (ABES) · doi:10.70675/2fb92711z373cz4b27z8082z7aa3f8930e63 · Cited by 1
Diversité des macrophages dans un modèle murin de stéatohépatite non alcoolique
Tran, S. (2019) · theses.fr (ABES) · doi:10.70675/22efc884z2788z43fazabc1zaeb115ea6833
Étude de la sensibilité à l’insuline du tissu adipeux en absence de production hépatique de glucose
Casteras, S. (2012) · theses.fr (ABES) · doi:10.70675/7b0400e0z9e49z4df6za2c1z0c19ce63d0ca
Rôle de LECT2 dans les maladies stéatosiques non alcooliques du foie
Pham, S. (2020) · theses.fr (ABES) · doi:10.70675/3693bfe6z9d91z4045za9a9zc37497dc9c1b
Influence du sexe dans la susceptibilité aux hépatopathies métaboliques
Smati, S. (2019) · theses.fr (ABES) · doi:10.70675/01997f55za990z41e6z96baz8221de2a6281
Autophagy in the interplay between shear stress and kidney epithelium homeostasis
Roccio, F. (2021) · theses.fr (ABES) · doi:10.70675/899d5d97z1062z453cza091zcae756198817
Design and evaluation of therapeutic particles modulating autophagy
Zagkou, S. (2021) · theses.fr (ABES) · doi:10.70675/945352cczdaf3z45fczb8dezdc79d3ca5100
Recazens, E. (2021) · theses.fr (ABES) · doi:10.70675/5b66fe82zcbbbz4251z98c0z2bb967f598c2
Inter-organ communication in physiology and pathophysiology : a role for the ChREBP-FGF21 axis?
Carbinatti, T. (2024) · theses.fr (ABES) · doi:10.70675/5d147ab4zad37z4f6bzac51z32a08efeaa51
Metadata
- Authors
- Benhamed, F., Denechaud, P.-D., Lemoine, M., Robichon, C., Moldes, M., Bertrand-Michel, J., Ratziu, V., Serfaty, L., Housset, C., Capeau, J., Girard, J., Guillou, H., & Postic, C.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Hôpital Saint-Antoine (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Pitié-Salpêtrière Hospital (FR)
- Toxicologie Alimentaire (FR)
- Institut Cochin (FR)
- Corresponding author
- Postic, Catherine
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2012-06-01
- Volume
- 122
- Issue
- 6
- Pages
- 2176-2194
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3366390
- OpenAlex
- W2117220292
- Cited by
- 408
- References
- 94
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 22 · 2023: 35 · 2022: 27 · 2021: 28 · 2020: 34 · 2019: 23 · 2018: 25 · 2017: 35 · 2016: 27 · 2015: 30 · 2014: 41 · 2013: 27 · 2012: 13
- FWCI
- 26.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- HAL Portal Artxiker (Hindustan Aeronautics Limited (India)) (submittedVersion)
- Funders
- European Commission
- Agence Nationale de la Recherche
- Institut National de la Santé et de la Recherche Médicale (U1016)
- Association Française pour l'Etude du Foie (AFEF-2008)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- ChREBP, carbohydrate-responsive element-binding protein, hepatic steatosis, insulin resistance, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, lipogenesis, fatty acid esterification, stearoyl-CoA desaturase 1, monounsaturated fatty acids, Akt phosphorylation, insulin signaling, glucose tolerance, high-fat diet, lipidomics, hepatocytes
- MeSH terms
- Animals, Fatty Acids, Monounsaturated, Fatty Liver, Female, Humans, Insulin Resistance, Liver, Male, Nuclear Proteins, Phosphorylation, Stearoyl-CoA Desaturase, Transcription Factors, Metabolic Syndrome, Lipogenesis, Proto-Oncogene Proteins c-akt, Mice, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.